Table 1 Overview of values for key clinical parameters of samples from the LRRK2 cohort consortium: age at sampling, age at onset, age at diagnosis, disease duration, familial history (y/n), Levodopa Equivalent Daily Dose (LEDD), Unified Parkinson’s disease rating scale III (UPDRS III), modified Hoehn and Yahr Stage, Modified Schwab and England Consensus Rating, Montreal Cognitive Assessment (MoCA).
Descriptor | LRRK2-/PD- n = 19 | LRRK2−/PD+ n = 20 | LRRK2+/PD− n = 14 | LRRK2+/PD+ n = 15 | Statistical summarya |
|---|---|---|---|---|---|
Age at sampling (years), mean ± SD (median) | 61.3 ± 10.9 (61) | 62.6 ± 8.4 (62) | 60.3 ± 12.9 (59.5) | 66.1 ± 11.5 (71) | n.s.b |
Age at onset (years), mean ± SD (median) | NA | 56.1 ± 24.4 (55) | NA | 55.1 ± 12.6 (58) | n.s. |
Age at diagnosis (years), mean ± SD (median) | NA | 58 ± 20 (58) | NA | 57.2 ± 19.5 (61) | n.s. |
Disease duration (years), mean ± SD (median) | NA | 5.9 ± 3.1 (6) | NA | 11.1 ± 5.6 (10) | 0.0018 |
Familial History of PD, n= total no/total yes | 4/15 | 12/8 | 1/13 | 5/10 | 0.118c |
LEDD mg, mean ± SD (median) | NA | 566 ± 406 (550) | NA | 1060 ± 725 (835) | 0.0861 |
UPDRS III, mean ± SD (median) | NA | 25.8 ± 10.5 (25) | NA | 22.6 ± 8.9 (24) | n.s. |
Modified Hoehn and Yahr score, mean ± SD (median) | NA | 2 ± 0.3 (2) | NA | 2.5 ± 0.8 (2) | 0.0206 |
Schwab and England, mean ± SD (median) | NA | 90.3 ± 7 (90) | NA | 71.4 ± 19 (80) | 0.0008 |
MoCA, mean ± SD (median), out of 30 | 26.4 ± 2.5 (27) | 25.9 ± 3.2 (27) | 25.6 ± 3.6 (26.5) | 22.4 ± 4.3 (23) | 0.0145 for LRRK2+/PD+, n.s. for LRRK2−/PD+ and LRRK2+/PD−b |
